SAS. Hamoud and E. Harding (2026). Euglycemic Ketoacidosis Induced by Dapagliflozin in a Non-Diabetic Patient With Cardiac Amyloidosis. Clinical case reports, 14(1), e71818. https://doi.org/10.1002/ccr3.71818

PubMed 41509085

[Abstract]
Dapagliflozin, though beneficial in heart failure, can rarely cause euglycemic ketoacidosis even in non-diabetic patients. Clinicians should maintain a high index of suspicion for metabolic acidosis in patients on SGLT2 inhibitors presenting with unexplained illness, regardless of blood glucose level.